Understanding Gender Dysphoria in Adolescence
A research briefing focused on the AFAB teen surge, autism overlap, social/peer influence, outcomes, and non-medical treatment evidence.
Compiled May 2026 · Evidence base includes peer-reviewed studies, systematic reviews (Cass, HHS, Karolinska/SBU, Finland COHERE), detransitioner survey data, and clinical writings.
How to use this briefing. Each section below is a standalone file with its own TL;DR and detailed findings. Presented are mainstream affirmative-care views, the systematic-review evidence that has reshaped European policy, and clinical perspectives from practitioners working with this population — with citations throughout so you can read the source material directly.
Quick Overview
- The population has changed. Until ~2010, gender dysphoria presented mostly in young children (usually boys) with persistent, early-childhood onset. Since ~2012, gender clinics worldwide have been overwhelmed by a new cohort: adolescent girls, usually with no childhood history, who come out as trans in their teens — often after social-media immersion and frequently in peer-group clusters.
- Autism and autistic traits are massively overrepresented. Studies find ASD prevalence of 11% (pooled) up to 14–68% in clinic-referred GD youth, vs. ~1–2% in the general population. Undiagnosed autism in girls is itself a well-documented blind spot in medicine.
- The evidence base for medical "affirmation" of teens is weak. Systematic reviews in the UK (Cass, 2024), Sweden (SBU, 2019; Karolinska, 2021), Finland (COHERE, 2020), and the US (HHS, 2025) all concluded the evidence for puberty blockers and cross-sex hormones in adolescents is low-quality and the risk/benefit ratio is uncertain. Most of these countries have now restricted these interventions to research settings.
- Detransition is more common than older numbers suggested, especially in the new AFAB adolescent cohort. The most-cited reasons in detransitioner surveys: realizing dysphoria was actually trauma/mental-health/internalized homophobia (58–70%), health concerns, transition not relieving distress.
- Psychotherapy-first approaches (exploratory, developmental, trauma-informed) are now the recommended first line in the UK and several European systems. The evidence base for them is also limited, but the risk profile is far lower than irreversible medical interventions.
- What's genuinely uncertain: the underlying cause(s) of gender dysphoria, whether "social contagion" is a real driver (or a stigmatizing frame), long-term outcomes of teens transitioned under the affirmative model, and which sub-groups benefit from which interventions.
Research Sections
Section 1
Etiology & the AFAB adolescent surge
What's known and hypothesized about causes, the historic sex-ratio inversion since ~2010, and competing explanatory models.
Section 2
Autism, neurodivergence & gender
The 3–10× overrepresentation, why undiagnosed autistic girls are a high-risk group, and the specific mechanisms (sensory, literal thinking, social).
Section 3
Social contagion & ROGD
Littman's hypothesis, the Diaz-Bailey replication and its retraction, peer-cluster data, the role of social media (TikTok, Tumblr, YouTube), and the live scientific debate.
Section 4
Outcomes — transition & detransition
Long-term mental-health outcomes, detransition rates (and why old numbers are likely undercounts), Vandenbussche & Littman 100-detransitioner survey findings, and the Cass / HHS / Karolinska reviews.
Section 5
Non-affirmative treatment approaches
Exploratory therapy (GETA, Cass-informed psychotherapy), attachment-based family therapy, treating comorbidities first, and what successful resolution without transition tends to look like.
Section 6 · News
Recent developments — 2025 & 2026
Skrmetti SCOTUS ruling, the first US detransitioner malpractice verdict, ASPS reversing on minor surgery, the new Finnish register study showing no mental-health benefit, Texas Children's settlement, NHS implementation progress.
A note on the evidence landscape
Honest framing. This is one of the most contested topics in medicine right now. Major US medical associations (AAP, Endocrine Society, APA) still endorse the affirmative-care model. European systematic reviews and the 2025 US HHS review reached substantially more cautious conclusions about the evidence base for adolescent medical transition. Detransitioner data is robust enough that the phenomenon is no longer dismissed, but the rate is genuinely unknown because follow-up in studies is short and many detransitioners disengage from clinics.
A reasonable, well-informed clinician can read the same studies and reach different conclusions — and that is itself meaningful information for a parent. The evidence does not support a single, confident, universally applicable treatment recipe for adolescents like your daughter. It does support taking the full clinical picture seriously: comorbidities, family dynamics, sensory issues, peer/online influences, and the developmental trajectory — and not collapsing the assessment into a single binary question about gender.
Cited Sources and Resources
Systematic Reviews & Government Reports
Peer-Reviewed Studies & Meta-Analyses
Detransition & Outcomes Research
Treatment Approaches & Clinical Models
Policy, Legal & Institutional Developments
Commentary, Advocacy & Further Reading